Alemtuzumab: The advantages and challenges of a novel therapy in MS

Neurology

Volumn 83, Issue 1, 2014, Pages 87-97

  Menge, Til ^a   Stüve, Olaf ^b,c   Kieseier, Bernd C ^b,c   Hartung, Hans Peter ^b,c  

^a Department of Neurology and Center for Neuropsychiatry ^*  (United States)

^b Department of Orthopedic Surgery   (Germany)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

AGRANULOCYTOSIS; ASPIRATION PNEUMONIA; ATRIAL FIBRILLATION; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; B LYMPHOCYTE; BRAIN HEMORRHAGE; BURKITT LYMPHOMA; ESOPHAGUS CANDIDIASIS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; GRAVES DISEASE; HEADACHE; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HYPERTHYROIDISM; INFUSION RELATED REACTION; LISTERIA MENINGITIS; LYMPHOCYTOPENIA; MILD RENAL IMPAIRMENT; MULTIPLE SCLEROSIS; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PASTEURELLOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SEPSIS; T LYMPHOCYTE; THYROID CANCER; IMMUNOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84904020925     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000540     Document Type: Review

References (45)

1. Menge T, Hartung HP, Kieseier BC. Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now. J Neurol 2011;258: 904-907.
2. Lemtrada. Available at: Www.ema.europa.eu/ema/index.jsp?curl5pages/medicines/human/medicines/003718/human-med-001678.jsp&;mid5WC0b01ac058001d124. Accessed October 14, 2013.
3. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012;380:1819-1828.
4. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after diseasemodifying therapy: A randomised controlled phase 3 trial. Lancet 2012;380:1829-1839.
5. Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement. Blood 1983;62:873-882.
6. Hale G, Cobbold SP, Waldmann H, et al. Isolation of low-frequency class-switch variants from rat hybrid myelomas. J Immunol Methods 1987;103:59-67.
7. Waldmann H, Hale G. Campath: from concept to clinic. Philos Trans R Soc Lond B Biol Sci 2005;360:1707-1711.
8. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-327.
9. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002;99:3554-3561.
10. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J Neurol 2006; 253:98-108.
11. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-1801.
12. Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83:298-304.
13. Cossburn MD, Harding K, Ingram G, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 2013;80: 55-61.
14. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78:1069-1078.
15. Comi G. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther 2009;31: 1142-1157.
16. Coles A, Deans J, Compston A. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 2004;106:270-274.
17. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10:338-348.
18. Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010;133:2232-2247.
19. Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: Recurrence of disease activity despite switching to glatiramer acetate. J Neurol 2011;258:1665-1669.
20. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-1097.
21. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-1107.
22. Riminton DS, Hartung HP, Reddel SW.Managing the risks of immunosuppression. Curr Opin Neurol 2011;24:217-223.
23. Lobermann M, Borso D, Hilgendorf I, et al. Immunization in the adult immunocompromised host. Autoimmun Rev 2011;11:212-216.
24. Jones JL, Coles AJ. Spotlight on alemtuzumab. Int MS J 2009;16:77-81.
25. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011;77:573-579.
26. Daniels GH, Vladic A, Brinar V, et al. Alemtuzumabrelated thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 2014;99:80-89.
27. Walsh M, Chaudhry A, Jayne D. Long- Term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (campath-1H). Ann Rheum Dis 2008;67:1322-1327.
28. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: A randomized, three- Arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-180.
29. Broadley SA, Deans J, Sawcer SJ, et al. Autoimmune disease in first-degree relatives of patients with multiple sclerosis: A UK survey. Brain 2000;123:1102-1111.
30. Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metab 2009;23: 693-702.
31. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 2009;7: 911-918.
32. Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 2011;118:6299-6305.
33. Pedchenko V, Bondar O, Fogo AB, et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 2010;363:343-354.
34. Ooi JD, Phoon RK, Holdsworth SR, Kitching AR. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J Am Soc Nephrol 2009;20:980-989.
35. Ooi JD, Holdsworth SR, Kitching AR. Advances in the pathogenesis of Goodpasture's disease: from epitopes to autoantibodies to effector T cells. J Autoimmun 2008; 31:295-300.
36. Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med 2008;359:768-769.
37. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
38. Jones JL, Thompson SA, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci USA 2013;110: 20200-20205.
39. Wiendl H, Kieseier B. Multiple sclerosis: Reprogramming the immune repertoire with alemtuzumab in MS. Nat Rev Neurol 2013;9:125-126.
40. Stellmann JP, Neuhaus A, Herich L, et al. Placebo cohorts in phase-3 MS treatment trials: predictors for on- Trial disease activity 1990-2010 based on a metaanalysis and individual case data. PLoS One 2012;7: E50347.
41. Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short- Term trials. Neurology 2011;76:S14-S25.
42. Bergamaschi R, Quaglini S, Tavazzi E, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler Epub 2012 May 31.
43. Kieseier BC, Stuve O. A critical appraisal of treatment decisions in multiple sclerosis: old versus new. Nat Rev Neurol 2011;7:255-262.
44. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255:231-238.
45. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119:225-237.